Advertisement
Review Article| Volume 36, ISSUE 2, P87-92, April 2018

Download started.

Ok

Genetic Predisposition to Rosacea

Published:December 16, 2017DOI:https://doi.org/10.1016/j.det.2017.11.002

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Dermatologic Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Elsaie M.L.
        • Choudhary S.
        Updates on the pathophysiology and management of acne rosacea.
        Postgrad Med. 2009; 121: 178-186
        • Two A.M.
        • Wu W.
        • Gallo R.L.
        • et al.
        Rosacea part I. Introduction, categorization, histology, pathogenesis, and risk factors.
        J Am Acad Dermatol. 2015; 72: 749-758
        • Steinhoff M.
        • Urgen Schauber J.
        • Leyden J.J.
        New insights into rosacea pathophysiology: a review of recent findings.
        J Am Acad Dermatol. 2013; 69: S15-S26
        • Holmes A.D.
        • Steinhoff M.
        Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics.
        Exp Dermatol. 2017; 26: 659-667
        • Melnik B.
        Rosacea: the blessing of the Celts – An approach to pathogenesis through translational research.
        Acta Derm Venereol. 2016; 96: 147-156
        • Selvaraj P.
        Vitamin D, vitamin D receptor, and cathelicidin in the treatment of tuberculosis.
        Vitam Horm. 2011; 86: 307-325
        • Roby K.D.
        • Nardo A.D.
        Innate immunity and the role of the antimicrobial peptide cathelicidin in inflammatory skin disease.
        Drug Discov Today Dis Mech. 2013; 10: e79-e82
        • Chosidow O.
        • Cribier B.
        Epidemiology of rosacea: updated data.
        Ann Dermatol Venereol. 2011; 138: S179-S183
        • Abram K.
        • Silm H.
        • Maaroos H.-I.
        • et al.
        Risk factors associated with rosacea.
        J Eur Acad Dermatol Venereol. 2010; 24: 565-571
        • Steinhoff M.
        • Buddenkotte J.
        • Aubert J.
        • et al.
        Clinical, cellular, and molecular aspects in the pathophysiology of rosacea.
        J Investig Dermatol Symp Proc. 2011; 15: 2-11
        • Helfrich Y.R.
        • Maier L.E.
        • Cui Y.
        • et al.
        Clinical, histologic, and molecular analysis of differences between erythematotelangiectatic rosacea and telangiectatic photoaging.
        JAMA Dermatol. 2015; 151: 825
        • Chang A.L.S.
        • Raber I.
        • Xu J.
        • et al.
        Assessment of the genetic basis of rosacea by genome-wide association study.
        J Invest Dermatol. 2015; 135https://doi.org/10.1038/jid.2015.53
        • Hafler D.A.
        • Compston A.
        • Sawcer S.
        • et al.
        • International Multiple Sclerosis Genetics Consortium
        Risk alleles for multiple sclerosis identified by a genome-wide study.
        N Engl J Med. 2007; 357: 851-862
        • Anderson C.A.
        • Boucher G.
        • Lees C.W.
        • et al.
        Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47.
        Nat Genet. 2011; 43: 246-252
        • Dajnoki Z.
        • Béke G.
        • Kapitány A.
        • et al.
        Sebaceous gland-rich skin is characterized by TSLP expression and distinct immune surveillance which is disturbed in rosacea.
        J Invest Dermatol. 2017; 137https://doi.org/10.1016/j.jid.2016.12.025
        • Chen Y.
        • Moore C.D.
        • Zhang J.Y.
        • et al.
        TRPV4 moves toward center-fold in rosacea pathogenesis.
        J Invest Dermatol. 2017; 137: 801-804
        • Mascarenhas N.
        • Wang Z.
        • Chang Y.
        • et al.
        TRPV4 mediates mast cell activation in cathelicidin-induced rosacea inflammation.
        J Invest Dermatol. 2017; 137: 972-975
        • Moore C.
        • Cevikbas F.
        • Pasolli H.
        • et al.
        UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling.
        Proc Natl Acad Sci U S A. 2013; 110: E3225-E3234
        • Aldrich N.
        • Gerstenblith M.
        • Fu P.
        • et al.
        Genetic vs environmental factors that correlate with rosacea.
        JAMA Dermatol. 2015; 151: 1213
        • Second J.
        • Korganow A.-S.
        • Jannier S.
        • et al.
        Rosacea and demodicidosis associated with gain-of-function mutation in STAT1.
        J Eur Acad Dermatol Venereol. 2017; https://doi.org/10.1111/jdv.14413
        • Egeberg A.
        • Hansen P.R.
        • Gislason G.H.
        • et al.
        Clustering of autoimmune diseases in patients with rosacea.
        J Am Acad Dermatol. 2016; https://doi.org/10.1016/j.jaad.2015.11.004
        • Valentonyte R.
        • Hampe J.
        • Huse K.
        • et al.
        Sarcoidosis is associated with a truncating splice site mutation in BTNL2.
        Nat Genet. 2005; 37: 357-364
        • Rallis E.
        • Korfitis C.
        Isotretinoin for the treatment of granulomatous rosacea: case report and review of the literature.
        J Cutan Med Surg. 2012; 16: 438-441
        • Van Steensel M.A.M.
        • Badeloe S.
        • Winnepenninckx V.
        • et al.
        Granulomatous rosacea and Crohn’s disease in a patient homozygous for the Crohn-associated NOD2/CARD15 polymorphism R702W.
        Exp Dermatol. 2008; 17: 1057-1058
        • Watanabe T.
        • Kitani A.
        • Murray P.J.
        • et al.
        NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses.
        Nat Immunol. 2004; 5: 800-808
        • Henckaerts L.
        • Vermeire S.
        NOD2/CARD15 disease associations other than Crohn's disease.
        Inflamm Bowel Dis. 2007; 13: 235-241